HIC
VRTX icon

Hamrick Investment Counsel’s Vertex Pharmaceuticals VRTX Stock Holding History

Hamrick Investment Counsel’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.63M Sell
3,286
-1,223
-27% -$542K 1.08% 24
2026
Q1 		$2.01M Buy
4,509
+1,526
+51% +$712K 1.12% 24
2025
Q4 		$1.35M Buy
+2,983
New +$1.29M 1.01% 28

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Hamrick Investment Counsel's VRTX Position: Q2 2026 in Review

Hamrick Investment Counsel reduced its Vertex Pharmaceuticals (VRTX) stake by 27% in Q2 2026, selling an estimated $542K and leaving 3,286 shares worth $1.63M. The position accounts for 1.08% of the portfolio, ranked #24.

Hamrick Investment Counsel first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.01M in Q1 2026. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Hamrick Investment Counsel held 3,286 shares of Vertex Pharmaceuticals worth $1.63M as of Q2 2026.
  • Hamrick Investment Counsel sold 1,223 Vertex Pharmaceuticals shares in Q2 2026, an estimated $542K.
  • Vertex Pharmaceuticals made up 1.08% of Hamrick Investment Counsel's portfolio in Q2 2026, its #24 holding.
  • Hamrick Investment Counsel first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Hamrick Investment Counsel's Vertex Pharmaceuticals position peaked at $2.01M in Q1 2026.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Hamrick Investment Counsel's 13F filing for Q2 2026, filed 13 Aug 2026.